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Abstract 
Background: DIXDC1 (Dishevelled-Axin domain containing 1) is a positive regulator of the Wnt pathway. In the field 
of cancer research, the role of DIXDC1 is unclear. Our previous in vitro study showed that DIXDC1 enhances β-catenin 
nuclear accumulation in gastric cancer cell lines. The aim of this study was to detect the expression of DIXDC1 in dif-
ferent histological subtypes of gastric carcinoma and to evaluate the correlation between the expression of DIXDC1 
and β-catenin localization and clinicopathological parameters, including patients’ survival.
Methods: Immunohistochemical staining was performed to characterize the expression of DIXDC1 and β-catenin in 
archived materials from 259 cases of gastric carcinoma. The χ2 test and the Fisher’s test were used to analyze correla-
tions between DIXDC1 expression, β-catenin localization, and clinicopathological parameters. Univariate analyses 
were performed using the Kaplan–Meier method, and the survival difference between groups was assessed by the 
log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model.
Results: Positive DIXDC1 staining was detected in tumor cells in 123 of 259 (47.5 %) cases. DIXDC1 expression in gas-
tric carcinoma was significantly correlated with the histological intestinal-type (P < 0.001), the depth of tumor invasion 
(P < 0.001) and the lymph node metastasis (P = 0.006). In the intestinal-type, DIXDC1 was correlated with the nuclear 
and cytoplasmic β-catenin expression (P = 0.002). Kaplan–Meier analysis indicated that patients with high DIXDC1 
expression had poor disease-specific survival (P < 0.001), especially in the intestinal-type. Moreover, multivariate 
regression analysis showed that positive expression of DIXDC1 was an independent prognostic predictor of intestinal-
type gastric carcinoma.
Conclusion: Our study indicated that DIXDC1 is a significant independent prognostic indicator in intestinal-type 
gastric carcinoma that plays an important role in carcinogenesis and progression of gastric carcinoma through the 
Wnt signaling pathway.
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Background
Gastric carcinoma (GC) is one of the leading causes 
of cancer-related death, especially in Asia. Gastric 
carcinogenesis can be considered a multistep process 
that involves specific genetic alterations. Dysregulation 
of Wnt signal transduction plays an important role in 
gastric carcinogenesis, especially in the development of 
intestinal-type gastric carcinoma [1–6].
DIXDC1 is the human homolog of Ccd1 (Coiled-coil-
Dishevelled-Axin1), a DIX (Dishevelled-Axin) domain-
containing protein and a positive regulator of the Wnt 
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pathway in zebrafish neural patterning [7]. In the Wnt 
signaling pathway, the DIX domain is involved in both 
homomeric and heteromeric complexes between Axin 
and Dishevelled (Dvl) that form the multiprotein com-
plexes of adenomatous polyposis coli (APC), glycogen 
synthase kinase 3 beta (GSK-3β), and β-catenin, which 
regulate T-cell-factor (TCF) signaling [8, 9]. In the field 
of cancer research, the role of DIXDC1 is unclear. Recent 
studies have shown that overexpression of DIXDC1 can 
increase the proliferation of colon cancer cells [10] and 
the invasion and migration ability of non-small cell lung 
cancer (NSCLC) [11], both of which are affected by the 
PI3  K/AKT pathway. Our previous study showed that 
DIXDC1 is overexpressed in gastric cancer (37/66) and 
that the upregulation of DIXDC1 is associated with poor 
prognosis. We also found that DIXDC1 promotes gastric 
cancer cell invasion and metastasis through the activa-
tion of the Wnt pathway [12].
Beta-catenin is a key factor of the Wnt pathway that 
is phosphorylated by GSK-3β and then degraded by the 
ubiquitin–proteasome system. Accumulation of cyto-
plasmic β-catenin results in its entry into the nucleus 
where it binds to the members of the TCF family and 
activates downstream target genes, such as c-myc and 
cyclin D1, which are involved in cell proliferation [13–
17]. However, the regulatory mechanism of β-catenin sta-
bilization is not yet completely understood. Our previous 
study showed that DIXDC1 enhances β-catenin nuclear 
localization by decreasing the phosphorylation level of 
β-catenin [12]. All of the results of in vitro experiments 
are needed to further certify in gastric carcinoma tis-
sues. Therefore, the goals of this study are (a) to enlarge 
the sample size (259 cases) to further study the relation-
ship between DIXDC1 expression and clinicopatho-
logical features of gastric carcinoma and its effect on 
patients’ prognoses; (b) to explore the expression pattern 
of DIXDC1 and the subcellular localization of β-catenin 
in different histopathological subtypes of gastric carci-
noma (intestinal-type and diffuse-type); and (c) to verify 




The mean and median age of these patients was 59.2 and 
59.0 years old (range 30–87 years), respectively, and the 
male/female ratio was 3:1. Tumor size ranged from 0.4 
to 14 cm (mean, 3.9 cm; median, 3.5 cm). According to 
the tumor-node-metastasis (TNM) staging system of the 
American Joint Committee on Cancer (AJCC, 7th edi-
tion), 163 cases (62.9  %) were in disease stage I/II and 
96 cases (37.1  %) were in disease stage III/IV. Lymph 
node metastasis was observed in 154 cases (59.5 %). This 
cohort of gastric carcinomas was comprised of 151 cases 
of intestinal-type, 79 cases of diffuse-type, 25 cases of 
mixed-type and 4 cases of indeterminate-type. Follow-
up information was available on 195 patients and ranged 
from 2 to 96 months (median, 47 months). At the end of 
the follow-up period, 87 patients were still alive and 108 
had died of the disease. Disease-specific survival (DSS) at 
1, 3, and 5 years was 98.8, 90.3 and 27.8 %, respectively.
DIXDC1 expression in gastric carcinoma and its correlation 
with clinicopathological features
DIXDC1 was detected mainly in the cytoplasm of the 
tumor cells and displayed a diffuse pattern. Positive 
DIXDC1 staining was detected in 123 cases (47.5  %) of 
gastric carcinoma. Normal gastric mucosa was negative 
for DIXDC1 staining (Fig.  1). The relationship between 
DIXDC1 expression and histopathological character-
istics is summarized in Table 1. Positive DIXDC1 stain-
ing was detected in 97 of 151 cases of intestinal-type 
(64.2 %), 13 of 79 cases of diffuse-type (16.5 %), 12 of 25 
cases of mixed-type (48.0  %), and 1 of 4 cases of inde-
terminate-type (25.0  %) of gastric carcinoma. In some 
cases of mixed-type, positive DIXDC1 expression was 
only observed in the glandular areas, but not in the dif-
fuse regions (Fig.  1). Statistical analysis indicated that 
DIXDC1 protein expression was significantly correlated 
with the histological intestinal-type (P < 0.001). DIXDC1 
immunoreactivity was positively correlated with age 
(≥60 years, P < 0.001), the depth of invasion (P < 0.001) 
and the lymph node metastasis (P  =  0.006). However, 
there was no significant correlation between DIXDC1 
expression and other clinicopathological features such as 
gender (P = 0.086), size (≥5 cm, P = 0.141), tumor dif-
ferentiation (P  =  0.266) and clinical stage (P  =  0.056) 
(Table 1). 
Association between DIXDC1 expression 
and clinicopathological variables in intestinal‑type 
and diffuse‑type gastric carcinoma
DIXDC1 positive staining was observed more frequently 
in the intestinal-type of gastric carcinoma than in the 
diffuse-type. In the intestinal-type, but not in the dif-
fuse-type, DIXDC1 positive expression was correlated 
with age (≥60 years, P = 0.018), size (≥5 cm, P = 0.036), 
tumor differentiation (P =  0.003), the depth of invasion 
(P  <  0.001), the lymph node metastasis (P  <  0.001) and 
the clinical stage (P = 0.003) (Table 2).
Association of DIXDC1 with disease‑specific survival
The relationships of DIXDC1 expression with the 
disease-specific survival rates were also analyzed. 
As shown in Fig.  2, patients with DIXDC1-positive 
expression had a significantly poorer prognosis than 
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Fig. 1 Immunohistochemical staining of DIXDC1 in gastric carcinoma. a Normal gastric mucosa with negative DIXDC1 expression. (×200) b 
Diffuse-type GC with negative DIXDC1 expression. (×200) c Intestinal-type GC showing negative DIXDC1 expression. (×200) d Intestinal-type GC 
showing mild cytoplasmic staining of DIXDC1 (scored as 1). (×200) e Intestinal-type GC with moderate cytoplasmic DIXDC1 staining (scored as 2). 
(×200) f Intestinal-type GC with intense cytoplasmic DIXDC1 staining (scored as 3). (×200) g (×100) h In mixed-type cases, positive DIXDC1 expres-
sion was observed only in the glandular formation areas, but not in the diffuse regions. (×200)
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those without DIXDC1 expression (P  <  0.001). In 
the intestinal-type of gastric carcinoma, the disease-
specific survival rate of patients with DIXDC1-posi-
tive expression was also significantly lower than that 
of patients without DIXDC1 expression (P  <  0.001, 
Fig. 2). However, no difference in disease-specific sur-
vival rate was observed between DIXDC1-positive and 
negative groups in the diffuse-type of gastric carci-
noma (P = 0.848, Fig. 2).
 Univariate analysis of DSS in all cases revealed that, 
in addition to DIXDC1 expression (P  <  0.001), age 
(P =  0.003), tumor size (P =  0.015), the depth of inva-
sion (P < 0.001), lymph node metastasis (P < 0.001), and 
clinical stage (P  <  0.001) were all associated with DSS 
(Table  3). The other clinicopathological features, such 
as gender (P =  0.561), histological subtype (P =  0.940) 
and tumor differentiation (P = 0.205), were not statisti-
cally prognostic factors. Multivariate analysis showed 
that DIXDC1 expression was an independent prognostic 
indicator in gastric carcinoma (HR = 0.674, P = 0.037) 
in addition to the depth of invasion (HR  =  0.341, 
P = 0.011) and the clinical stage (HR = 0.272, P < 0.001) 
(Table  3). In the intestinal-type of gastric carcinoma, 
DIXDC1 expression was also a significant independent 
prognostic predictor (HR =  2.139, P =  0.036, Table  4). 
In addition, the depth of invasion also independently 
affected the disease-specific survival (HR  =  2.153, 
P = 0.001, Table 4). 
Localization of β‑catenin staining in gastric carcinoma
While our previous study showed that DIXDC1 
enhances β-catenin nuclear localization in  vitro [12], 
this has not been verified in gastric carcinoma tis-
sues. Thus, additional cases were utilized to show 
the relationship between DIXDC1 and β-catenin by 
immunohistochemistry.
The immunohistochemical staining patterns of 
β-catenin were divided into 4 types: negative, membra-
nous, cytoplasmic and nuclear staining patterns. Positiv-
ity with discontinuous or continuous distribution along 
the membrane or a very weak dotted expression were 
all included in the membranous pattern. We detected 
β-catenin expression using immunohistochemical stain-
ing in the 237 cases of gastric carcinoma mentioned 
above. In the normal gastric mucosa, β-catenin stain-
ing localized continuously to the cell membrane, while 
cytoplasmic and nuclear staining was generally absent 
(Fig.  3). As shown in Table  5, positive nuclear stain-
ing of β-catenin was observed in 75 (75/237, 31.6  %) 
cases of the total of 237 cases. Fifty-three cases exhibit-
ing nuclear accumulation of β-catenin were intestinal-
type gastric carcinoma (53/139, 38.1  %), while nuclear 
β-catenin localization was observed in 13 cases of dif-
fuse-type (13/70, 18.6  %), 8 cases of mixed-type (8/24, 
33.3 %), and 1 cases of indeterminate-type (1/4, 25.0 %). 
Cytoplasmic β-catenin staining was detected in 76 cases 
of gastric carcinoma (76/237, 32.1  %). Forty (40/139, 
28.8  %) cases of intestinal-type and 29 (29/70, 41.4  %) 
cases of diffuse-type showed cytoplasmic expression of 
β-catenin. Membranous β-catenin staining was noted 
in 57 (57/237, 24.1  %) cases, while lost expression of 
β-catenin was observed in 29 (29/237, 12.2  %) cases 
(Fig. 3). The localization of β-catenin was not correlated 
with all histopathological subtypes of gastric carcinoma 
(P  =  0.127) but was correlated with intestinal and dif-
fuse-type (P = 0.025). Nuclear β-catenin expression was 
observed more frequently in the intestinal-type than in 
the diffuse-type. 
Table 1 Correlation between DIXDC1 expression and clin-




DIXDC1 +  
(n = 123)




 Male 99 97
 Female 24 39
Age <0.001
 ≥60 years 77 52
 <60 years 46 84
Size 0.141
 ≥5 cm 39 32
 <5 cm 84 104
Differentiation 0.266
 High grade 47 43




 Intestinal 97 54
 Diffused 13 66
 Mixed 12 13
 Indeterminate 1 3
Depth of invasion <0.001
 T1 17 50
 T2 21 18
 T3 + T4 85 68
Lymph node   
metastases
0.006
 Negative 39 66
 Positive 84 70
Clinical stage 0.056
 I/II 70 93
 III/IV 53 43
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The relationship between DIXDC1 expression 
and β‑catenin localization in gastric carcinoma
We then determined the correlation of DIXDC1 immu-
noreactivity with β-catenin expression pattern in gastric 
carcinoma. In DIXDC1-positive cases, nuclear β-catenin 
staining was observed in 43 cases (43/115, 37.4  %) and 
cytoplasmic β-catenin staining was observed in 33 cases 
(33/115, 28.7  %). In those DIXDC1-negative staining 
cases, nuclear β-catenin staining was observed in 32 
cases (32/122, 26.2 %) and cytoplasmic β-catenin staining 
was observed in 43 cases (43/122, 35.2 %). However, no 
statistically significant association was observed between 
the DIXDC1 expression and the β-catenin localization 
(P = 0.243) in the cases overall. In intestinal-type gastric 
carcinoma, the patterns of β-catenin staining were sig-
nificantly different between the cases with and without 
Table 2 Correlation between DIXDC1 expression and clinicopathological parameters in two types of gastric carcinoma
Clinicopathological feature Intestinal‑type gastric carcinoma Diffuse‑type gastric carcinoma
DIXDC1 + (n = 97) DIXDC1 − (n = 54) P value DIXDC1 + (n = 13) DIXDC1 − (n = 66) P value
Gender 0.786 0.886
 Male 79 43 8 42
 Female 18 11 5 24
Age 0.018 0.072
 ≥60 years 59 22 8 23
 <60 years 38 32 5 43
Size 0.036 0.563
 ≥5 cm 27 7 5 20
 <5 cm 70 47 8 46
Differentiation 0.003 –
 High grade 40 36 0 0
 Low grade 57 18 13 66
Depth of invasion <0.001 0.756
 T1 13 29 3 18
 T2 18 6 1 9
 T3 + T4 66 19 9 39
Lymph node metastases <0.001 0.506
 Negative 30 37 6 24
 Positive 67 17 7 42
Clinical stage 0.003 0.650
 I/II 56 44 7 40
 III/IV 41 10 6 26
Fig. 2 The relationships of DIXDC1 expression and the disease-specific survival rates. a A positive association of DIXDC1 expression and a decrease 
in DSS (n = 195); b in the intestinal-type of gastric carcinoma, the DIXDC1-positive group exhibited a lower DSS compared with the DIXDC1-
negative group (n = 106); c in the diffuse-type of gastric carcinoma, no difference in DSS between the DIXDC1-positive and negative groups was 
observed (n = 64)
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DIXDC1 expression (P  =  0.002, Table  6). Nuclear and 
cytoplasmic expression of β-catenin were detected more 
frequently in the DIXDC1-positive expression group 
than in the DIXDC1-negative group. In addition, the 
immunohistochemistry results revealed that DIXDC1 
and β-catenin co-localized well in some tissue speci-
mens (Fig. 4). Even in cases with heterogeneous DIXDC1 
expression, strong β-catenin expression was detected in 
the DIXDC1-positive staining area, while it was absent in 
the DIXDC1-negative staining area (Fig. 4). 
Discussion
One of the most commonly used classifications of gastric 
carcinoma is the Lauren classification. According to the 
criteria of Lauren [18], gastric carcinomas are divided 
into two major categories: (a) intestinal-type or well-
differentiated carcinoma growing primarily in glandular 
formation and (b) diffuse-type or poorly differentiated 
carcinoma primarily not forming glands and showing 
scattered cell growth with loose cell-to-cell adhesion. 
Tumors that contain approximately equal quantities of 
intestinal and diffuse components are called mixed-type. 
Carcinomas too undifferentiated to fit into each category 
are put into the indeterminate category (atypical type). 
The molecular alterations leading to these histological 
patterns are significantly different. The intestinal-type of 
gastric carcinoma is known to be very similar to that of 
colon carcinogenesis [1–4]. Mutations of the Wnt path-
way genes APC and β-catenin can only be detected in 
a small portion of gastric carcinomas [6]. However, the 
mutations were observed more frequently in intestinal-
type gastric cancer than in diffuse-type. Therefore, the 
canonical Wnt pathway was thought to participate in 
intestinal-type gastric carcinoma development and pro-
gression. However, E-cadherin mutation is a frequent 
genetic alteration in diffuse-type gastric cancer [19, 20].
Human DIXDC1 was identified as an Axin2 C-terminus 
interaction protein [21, 22]. The DIX domain is impor-
tant for mediating multiple signal transductions [9, 23], 
and, in the Wnt signaling pathway, DIXDC1 is involved 
in both homomeric and heteromeric complexes between 
Axins and Dvl that form the multiprotein complexes of 
APC, GSK-3, and β-catenin, which regulate T-cell-factor 
(TCF) signaling [8, 9]. There have been a few studies on 
the biological role of human DIXDC1 so far. Previously, 
DIXDC1 was reported to be an Actin-binding protein 
and presumed to be connected with cell movement [21]. 
The overexpression of DIXDC1 can increase the invasion 
and migration ability of NSCLC [11]. Our previous study 
showed that overexpression of DIXDC1 can be observed 
in colorectal carcinoma and gastric carcinoma, and can 
increase the proliferation of colon cancer cells [10] and 
the invasion and migration ability of gastric cancer cells 
[12].
In this study, we expanded the number of gastric car-
cinoma samples to examine the correlation between 
DIXDC1 expression level and clinicopathological param-
eters, including patients’ prognoses. We found that posi-
tive expression of DIXDC1 can be detected in 47.5 % of 
gastric carcinoma. We also identified significant asso-
ciations between DIXDC1 expression and the depth 
of tumor invasion (T), lymph node metastasis (N) and 
disease-specific survival, which suggested that DIXDC1 
plays an important role in gastric carcinoma. Addition-
ally, we found that the expression of DIXDC1 was sig-
nificantly correlated with histological subtype of gastric 
carcinoma, and it was more commonly detected in the 
intestinal-type (64.2 %) than in the diffuse-type (16.5 %). 
In the intestinal-type group, DIXDC1 expression was 
associated with age (≥60 years), tumor size (≥5 cm), dif-
ferentiation, the depth of invasion, lymph node metasta-
sis and clinical stage. However, there was no correlation 
between DIXDC1 expression and the clinicopathological 
parameters mentioned above in the diffuse-type group. 





P value HR 95 % CI P value
Gender 0.561 – – –
Age 0.003 0.885 0.584–1.342 0.565
Size 0.015 0.941 0.618-1.433 0.778
Differentiation 0.205 – – –
Histological subtype 0.940 – – –
Depth of invasion <0.001 0.341 0.149–0.781 0.011
Lymph node metastases <0.001 1.053 0.566–1.959 0.871
Clinical stage <0.001 0.272 0.151–0.491 <0.001
DIXDC1 <0.001 0.647 0.430–0.975 0.037





P value HR 95 % CI P value
Gender 0.420 – – –
Age 0.004 1.588 0.904–2.787 0.108
Size 0.029 1.163 0.631–2.143 0.325
Differentiation 0.131 – – –
Depth of invasion <0.001 2.153 1.377–3.368 0.001
Lymph node metastases <0.001 1.372 0.731–2.577 0.325
Clinical stage 0.271 – – –
DIXDC1 <0.001 2.139 1.052–4.349 0.036
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Similar to our previously published data [12], we found 
that patients with DIXDC1-positive expression had sig-
nificantly poorer prognoses than those without DIXDC1 
expression in allcases. However, the above result was 
observed in the intestinal-type group but not in the 
diffuse-type. As a result of expanding the sample size, 
we found that DIXDC1 may play an important role in 
carcinogenesis and progression of the intestinal-type of 
gastric carcinoma.
Cytoplasmic and/or nuclear localization of β-catenin 
can be used to estimate the activation of the Wnt path-
way. The expression patterns of β-catenin in gastric car-
cinoma tissue were detected in this study, and the results 
showed that β-catenin nuclear localization was detected 
more frequently in the intestinal-type than in the diffuse-
type. In contrast to colon cancer, mutation of β-catenin 
in gastric carcinoma is not as well-defined. The inci-
dence of β-catenin mutations was significantly different 
in different studies [3, 4, 24–29]. The mechanisms regu-
lating the Wnt signaling pathway in gastric carcinoma 
remained to be elucidated. Our previous in vitro experi-
ments showed that DIXDC1 interacted with β-catenin, 
inhibited the phosphorylation of β-catenin and increased 
the translocation of β-catenin to the nucleus in a gas-
tric carcinoma cell line, indicating that DIXDC1 could 
Fig. 3 Localization of β-catenin staining in gastric carcinoma. In the diffuse-type group, tumor cells without expression of β-catenin, while the nor-
mal gastric epithelia exhibit continuous cell membrane staining (a). In the intestinal-type group, nuclear localization of β-catenin (b), cytoplasmic 
β-catenin staining (c), continuous membrane staining of β-catenin (d). (×200)
Table 5 Localization of β-catenin staining in different his-





Cytoplasm Membrane Lost 
expression
Intestinal 53 (38.1) 40 (28.8) 31 (22.3) 15 (10.8)
Diffused 13 (18.6) 29 (41.4) 16 (22.9) 12 (17.1)
Mixed 8 (33.3) 5 (20.8) 9 (37.5) 2 (8.3)
Indeterminate 1 (25.0) 2 (50.0) 1 (25.0) 0 (0)
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positively regulate the Wnt signaling pathway [12]. In this 
study, we analyzed the co-localization of DIXDC1 and 
β-catenin in the tumor specimens to verify our in  vitro 
results. Cytoplasmic/nuclear localization of β-catenin 
was observed more frequently in the cases with positive 
DIXDC1 expression than those without DIXDC1 expres-
sion in intestinal-type gastric carcinoma. In addition, 
there was a very robust co-localization of DIXDC1 and 
β-catenin in the tissue specimens. Heterogeneous expres-
sion of DIXDC1 was observed in some areas of the 
Table 6 Relationship between DIXDC1 expression and localization of β-catenin staining in gastric carcinoma
β‑catenin Overall cases of gastric carcinoma Intestinal‑type of gastric carcinoma
DIXDC1 + (n = 115) DIXDC1 − (n = 122) P value DIXDC1 + (n = 90) DIXDC1 − (n = 49) P value
Nucleus 43 32 0.243 37 16 0.002
Cytoplasm 33 43 37 10
Membrane 24 33 13 21
Lost expression 15 14 3 2
Fig. 4 Co-localization of DIXDC1 and β-catenin expression in gastric carcinoma. Immunohistochemistry results showing strong DIXDC1 (a) and 
β-catenin staining (b) in the tumor area of the same case. (×200) In the case with heterogeneous DIXDC1 expression, strong β-catenin staining (d) 
was observed in the DIXDC1-positive staining area (c), while β-catenin was not observed in the area absent of DIXDC1 expression. (×100)
Page 9 of 11Wang et al. Cancer Cell Int  (2015) 15:120 
gastric cancer specimen, and β-catenin expression was 
also detected in these areas, which further validated our 
in vitro experiments.
Conclusions
The present study reveals, to our knowledge for the 
first time, that the expression of DIXDC1 is correlated 
with the histological subtype of gastric carcinoma, and 
DIXDC1 may participate in the activation of Wnt in the 
carcinogenesis and progression of the intestinal-type 
of gastric tumor. DIXDC1 is associated with biologi-
cally more aggressive phenotypes of gastric carcinoma, 
and DIXDC1-positive expression is an independent bio-
marker for poor prognosis, especially in intestinal-type 
gastric carcinoma.
Methods
Tumor specimens and clinical data collection
The study was approved by The Clinical Research Eth-
ics Committee of Fudan University Shanghai Cancer 
Center. Written informed consents were obtained from 
the patients. We collected 259 cases of primary gastric 
carcinoma from the files of the Department of Pathology, 
Fudan University Shanghai Cancer Center. Patients who 
suffered from familial cancer syndromes or were previ-
ously treated with chemotherapy were not included. All 
specimens were routinely processed and stained with 
hematoxylin and eosin (H&E) for histological examina-
tion. All cases were reviewed by two pathologists and the 
histological diagnoses were confirmed without discrep-
ancy. All cases were classified according to the Lauren 
classification as intestinal-type (n  =  151), diffuse-type 
(n  =  79), mixed-type (n  =  25) or indeterminate-type 
(n  =  4). Clinicopathological parameters, such as gen-
der, age at the time of diagnosis, tumor size, the depth of 
invasion, differentiation, lymph node metastasis and clin-
ical stage, were obtained from the medical records of the 
patients. A total of 195 patients were followed up after 
the surgery until April 30th, 2015 and were included in 
the survival analysis. The disease-specific survival (DSS) 
was defined as the length of time between the surgery 
and death, specifically from the cancer.
Immunohistochemical staining
Representative paraffin blocks containing tumor and nor-
mal mucosa from each case were selected for immunohis-
tochemical analysis of DIXDC1 and β-catenin expression. 
Four μm-thick sections of the paraffin-embedded tissues 
were cut and deparaffinized according to standard histo-
logical techniques. Endogenous peroxidase activity was 
blocked by soaking the slides in 0.3 % H2O2 in methanol 
for 30 min at 37 °C. Antigen retrieval was performed by 
high pressure  repair in 0.1  M citrate solution (pH 6.0) 
for 10  min followed by incubation with anti-DIXDC1 
polyclonal antibody (Cat. No. sc-292126, Santa Cruz 
Biotechnology, USA) diluted at 1:100 or anti-β-catenin 
monoclonal antibody (Cat. No. 610154, BD Biosciences, 
USA) diluted at 1:200. After an overnight incubation in 
primary antibodies at 4  °C, the slides were washed with 
PBS and then incubated for 60  min at room tempera-
ture with the biotinylated link antibody (Cat. No. K0609, 
Universal LSABTM2Kit/HRP, Rabbit/Mouse, Dako A/S, 
Denmark) diluted at 1:200. After being washed with PBS, 
the sections were stained with 0.05 % diaminobenzidine 
containing 0.01 % hydrogen peroxidase. Finally, the sec-
tions were counterstained with hematoxylin, dehydrated 
and mounted. Omission of the primary antibody and 
substitution by non-specific immunoglobins were used as 
negative controls.
Immunohistochemical evaluation
The sections were evaluated by two pathologists who 
were blinded to the clinical outcomes. The staining of 
DIXDC1 was coded as positive or negative (scored as 0). 
The positive cases were divided into weak (scored as 1), 
moderate (scored as 2) and strong (scored as 3) based on 
the staining intensity. The score was calculated by add-
ing the multiplication of the different staining intensities 
in the four gradations with each percentage of positive 
cells. The mean score for the duplicate scores from each 
pathologist was calculated for a final score from 0 to 
300 points. A tumor sample having a score  ≥50 points 
was considered positive [30]. The staining patterns of 
β-catenin were divided into four types: (1) lost expres-
sion; (2) membranous pattern, positivity with discon-
tinuous or continuous distribution along the membrane 
or a very weak dotted expression [31]; (3) cytoplasmic 
pattern; and (4) nuclear pattern, when β-catenin stain-
ing was observed in the nuclei of more than 10  % of 
the tumor cells, expression was considered positive for 
nuclear staining, even if it was previously reported to be 
associated with cytoplasmic and/or membranous stain-
ing [32].
Statistical analysis
The χ2 test and the Fisher’s test were used to test corre-
lations between DIXDC1 expression, β-catenin locali-
zation, and clinicopathological parameters, such as 
histological type, gender, age, tumor size, the depth of 
invasion, differentiation and lymph node metastasis. The 
χ2 test was also used for analyzing correlations between 
β-catenin expression pattern and histopathological sub-
type of gastric carcinoma. Univariate analyses were 
performed using the Kaplan–Meier method, and the sur-
vival difference between groups was assessed by the log-
rank test. Variables with a value of P < 0.05 were selected 
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for multivariate analysis. Multivariate analysis was per-
formed using the Cox proportional hazards regression 
model. Differences were considered to be significant at 
P < 0.05. SPSS (Chicago, IL) version 18.0 was used to ana-
lyze all of the data.
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